Clinical trials: Camrelizumab
Colorectal Cancer
A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC)
This is an open-label, single center, non-randomized, phase Ⅱ trial to evaluate safety and efficacy of using the combination treatment of Camrelizumab with anti-angiogenic drugs and Chemotherapy of metastatic colorectal mucinous…
- Trial name
- NCT04446091
- Testing
- Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.), Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.)+Irinotecan
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang Cancer Hospital
Head and Neck Squamous Cell Carcinoma
Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC
This study is a single arm phase II trial including 53 patients with T2N2-3M0、T3-4N0-3M0（III-IV） head and neck squamous cell carcinoma (HNSCC) eligible for resection, who receive neo-adjvuant Camrelizumab combined with cisplatin…
- Trial name
- NCT04826679
- Testing
- Camrelizumab, nab-paclitaxel, cisplatin
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Sun Yat-sen University
Resectable Esophageal Squamous Cell Carcinoma
Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.
The purpose of this study is to explore the effectiveness and safety of neoadjuvant immune combined chemotherapy or radiochemotherapy compared with traditional neoadjuvant radiochemotherapy in patients with locally advanced…
- Trial name
- NCT05043688
- Testing
- Camrelizumab, radiotherapy
- Where
- 5 sites in China
- Volunteers
- 426 people
- Sponsor
- Zhigang Li
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer
The study is being conducted to evaluate the efficacy, safety and tolerability of chemotherapy and apatinib with or without camrelizumab in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously…
- Trial name
- NCT04208347
- Testing
- Apatinib 250mg, Camrelizumab, S-1, Oxaliplatin
- Where
- 23 sites in China
- Volunteers
- 580 people
- Sponsor
- Ruijin Hospital
Breast Neoplasms
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
RATIONALE: Patients with HER2-negative advanced breast cancer have limited choice on targeted therapies, and often show only modest responses to available immunotherapies.
- Trial name
- NCT06121557
- Testing
- Surgery for harvesting tumor-draining lymph nodes, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received ≦ 1 Line of Chemotherapy
This is a phase II, single-arm, multi-center, prospective clinical study of camrelizumab in combination with liposomal doxorubicin and losartan in patients with advanced or locally advanced triple-negative breast cancer who had…
- Trial name
- NCT05097248
- Testing
- Camrelizumab, Liposomal Doxorubicin, Losartan
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Advanced Hepatocellular Carcinoma
Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study)
Compared to systemic therapy alone, conversion therapy is promising to improve the prognosis of patients with advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT05738616
- Testing
- Lenvatinib combined with TACE and Camrelizumab
- Where
- China
- Volunteers
- 196 people
- Sponsor
- Wen Tianfu
Advanced HER2 Negative Breast Carcinoma, HRD+Breast Cancer
Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer
This study is planned to include 40 patients with HER2-negative advanced breast cancer to receive fluzoparib combined with chidamide or fluzoparib combined with camrelizumab to observe and evaluate the efficacy and safety of…
- Trial name
- NCT05085626
- Testing
- fluzoparib+chidamide, fluzoparib+camrelizumab
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Ovarian Clear Cell Carcinoma
A Study of Camrelizumab in Combination With Anlotinib in Subjects Advanced Ovarian Clear Cell Carcinoma
This study is prospective ,open-label, single-center phase II clinical study. Target population is patients with advanced (stage III-IV) ovarian clear cell carcinoma.
- Trial name
- NCT05600998
- Testing
- Camrelizumab
- Volunteers
- 20 people
- Sponsor
- Peking University Third Hospital
Colorectal Cancer Metastatic, Liver Metastases
A Trial of Camrelizumab Combined With Microwave Ablation and Chemotherapy in the Treatment of Colorectal Cancer Liver Metastasis/Pulmonary Metastasis
Currently, comprehensive treatments for liver metastasis/pulmonary metastasis that cannot reach NED include systemic chemotherapy, interventional chemotherapy, molecular targeted therapy, immunotherapy, and local treatments…
- Conditions
- Colorectal Cancer Metastatic, Liver Metastases, Lung Metastases
- Trial name
- NCT04888806
- Testing
- Camrelizumab, ablation, chemotherapy
- Volunteers
- 37 people
- Sponsor
- Harbin Medical University
Oral Squamous Cell Carcinoma
Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma
The purpose of this study is to investigate the safety and feasibility of neoadjuvant PD-1 blockade alone or neoadjuvant PD-1 blockade plus TPF induction chemotherapy in subjects with resectable local advanced oral squamous cell…
- Trial name
- NEOPBOSCC (NCT04649476)
- Testing
- Camrelizumab, Camrelizumanb plus TPF
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Hospital of Stomatology, Wuhan University
PFS
Neoadjuvant Chemotherapy With Camrelizumab in Locally Advanced Esophageal Squamous Cell
A prospective, single arm, single center, phase II clinical trial of neoadjuvant chemotherapy with camrelizumab in locally advanced esophageal squamous cell,to evaluate the progression free survival
- Trial name
- NCT04520035
- Testing
- camrelizumab, Paclitaxel, Neoadjuvant Chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University